Protheracytes

COMBINATION_PRODUCT2 trials

Sponsors

CellProthera

Conditions

Acute Myocardial InfarctionHeart Attack

Phase 1

SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand)

WithdrawnNCT04198883

CellProtheraHeart Attack

Start: 2018-11-27End: 2021-07-31Updated: 2022-06-10

Phase 2

EXCELLENT (EXpanded CELL ENdocardiac Transplantation)

CompletedNCT02669810

CellProtheraAcute Myocardial Infarction

Start: 2016-02-10End: 2024-03-15Updated: 2026-03-19

Related Papers

TransEndocardial Injection of Autologous Expanded CD34<sup>+</sup> Stem Cells (ProtheraCytes<sup>®</sup>) after myocardial infarction: Impact on Patients' Quality of Life.

2026-03-03

Nose-to-brain delivery of stem cells in stroke: the role of extracellular vesicles.

2024-11-0112 citations

Development of a potency assay for CD34<sup>+</sup> cell-based therapy.

2023-11-114 citations